Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362526 | 0.77 | F2 (0.35) | CRBN | |
| SCHEMBL12252009 | 0.72 | — | — | |
| SCHEMBL3043 | 0.72 | — | — | |
| SCHEMBL8271652 | 0.72 | — | — | |
| SCHEMBL12360530 | 0.72 | — | — | |
| SCHEMBL2398125 | 0.72 | BRD4 (0.43) | CRBNKMT2AADRA2CBRD4BRD2 | |
| SCHEMBL9881318 | 0.71 | CRBN (0.33) | CRBNKMT2A | |
| SCHEMBL12748060 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL22443373 | 0.69 | — | — | |
| Water SCHEMBL3778195 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317013-B1 | NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME | MITSUBISHI CHEM CORP (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-20150196561-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-6942948-B2 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-09-13 | — | — | US | disclosed |
| US-20030165733-A1 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1317013-A1 | NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196561-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | SNCA, DRD1, DRD2 | CRBN 3819/4885KMT2A 2720/4885ADRA2C 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.